CD73 drugs for Non-Small Cell Lung Cancer
4 tracked CD73 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the CD73 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 31 Phase 2/31 Phase 11 preclinical / unstaged
Head-to-head evidence: Mavrostobart vs Mupadolimab · Mavrostobart vs Oleclumab · Mupadolimab vs Oleclumab · Mupadolimab vs Uliledlimab · Oleclumab vs Uliledlimab